The GreenBladder Study: Early Detection of Bladder Cancer in Greenland Using a Urinary Biomarker.

ABSTRACT: Background: Bladder cancer (BC) incidence in Greenland is lower than in other Nordic countries, yet mortality is disproportionately high, suggesting delayed detection. Cystoscopy is the diagnostic gold standard to detect BC, but access in Greenland is often limited by geographic and logistical challenges, underscoring the need for more accessible diagnostic tools. Objectives: This study evaluated the performance of the urinary biomarker test Xpert^® Bladder Cancer Detection (XBCD) among patients referred for cystoscopy within the Greenlandic healthcare system. Methods: In this prospective observational study, 198 patients referred for urological evaluation due to hematuria or other urologic symptoms were recruited from five Greenlandic towns. All participants

SUBMITTER: Fryd ND 

PROVIDER: S-EPMC12842550 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature